155 related articles for article (PubMed ID: 35484313)
1. Cytokinetic-driven myeloprotection after cytotoxic chemotherapy: from an old idea to a new clinical approach.
Sbrana A; Antonuzzo A; Danova M
Support Care Cancer; 2022 Sep; 30(9):7057-7060. PubMed ID: 35484313
[TBL] [Abstract][Full Text] [Related]
2. Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer.
Dómine Gómez M; Csőszi T; Jaal J; Kudaba I; Nikolov K; Radosavljevic D; Xiao J; Horton JK; Malik RK; Subramanian J
Int J Cancer; 2021 Oct; 149(7):1463-1472. PubMed ID: 34109630
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic antibiotics or G(M)-CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy.
Skoetz N; Bohlius J; Engert A; Monsef I; Blank O; Vehreschild JJ
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007107. PubMed ID: 26687844
[TBL] [Abstract][Full Text] [Related]
4. New Advances in Supportive Care: Chemoprotective Agents as Novel Opportunities in Geriatric Oncology.
Balducci L; Falandry C; List A
Curr Oncol Rep; 2022 Dec; 24(12):1695-1703. PubMed ID: 35986858
[TBL] [Abstract][Full Text] [Related]
5. Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials.
Ferrarotto R; Anderson I; Medgyasszay B; García-Campelo MR; Edenfield W; Feinstein TM; Johnson JM; Kalmadi S; Lammers PE; Sanchez-Hernandez A; Pritchett Y; Morris SR; Malik RK; Csőszi T
Cancer Med; 2021 Sep; 10(17):5748-5756. PubMed ID: 34405547
[TBL] [Abstract][Full Text] [Related]
6. Vinorelbine (Navelbine)/carboplatin combination therapy: dose intensification with granulocyte colony-stimulating factor.
Crawford J; O'Rourke MA
Semin Oncol; 1994 Oct; 21(5 Suppl 10):73-8. PubMed ID: 7526467
[TBL] [Abstract][Full Text] [Related]
7. A Proactive Approach to Prevent Hematopoietic Exhaustion During Cancer Chemotherapy in Older Patients: Temporary Cell-Cycle Arrest.
Balducci L; Falandry C; List A
Drugs Aging; 2023 Mar; 40(3):263-272. PubMed ID: 36715830
[TBL] [Abstract][Full Text] [Related]
8. Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies.
Weiss J; Goldschmidt J; Andric Z; Dragnev KH; Gwaltney C; Skaltsa K; Pritchett Y; Antal JM; Morris SR; Daniel D
Clin Lung Cancer; 2021 Sep; 22(5):449-460. PubMed ID: 33895103
[TBL] [Abstract][Full Text] [Related]
9. CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy.
Lai AY; Sorrentino JA; Dragnev KH; Weiss JM; Owonikoko TK; Rytlewski JA; Hood J; Yang Z; Malik RK; Strum JC; Roberts PJ
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33004541
[TBL] [Abstract][Full Text] [Related]
10. Intensification of chemotherapy for the treatment of solid tumours: feasibility of a 3-fold increase in dose intensity with peripheral blood progenitor cells and granulocyte colony-stimulating factor.
Leyvraz S; Ketterer N; Perey L; Bauer J; Vuichard P; Grob JP; Schneider P; von Fliedner V; Lejeune F; Bachmann F
Br J Cancer; 1995 Jul; 72(1):178-82. PubMed ID: 7541235
[TBL] [Abstract][Full Text] [Related]
11. Budget impact analysis of trilaciclib for decreasing the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer in the United States.
Abraham I; Goyal A; Deniz B; Moran D; Chioda M; MacDonald KM; Huang H
J Manag Care Spec Pharm; 2022 Apr; 28(4):435-448. PubMed ID: 35100006
[No Abstract] [Full Text] [Related]
12. Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer.
Woll PJ; Hodgetts J; Lomax L; Bildet F; Cour-Chabernaud V; Thatcher N
J Clin Oncol; 1995 Mar; 13(3):652-9. PubMed ID: 7533825
[TBL] [Abstract][Full Text] [Related]
13. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
Aapro MS; Bohlius J; Cameron DA; Dal Lago L; Donnelly JP; Kearney N; Lyman GH; Pettengell R; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
Eur J Cancer; 2011 Jan; 47(1):8-32. PubMed ID: 21095116
[TBL] [Abstract][Full Text] [Related]
14. Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor.
Nichols CR; Fox EP; Roth BJ; Williams SD; Loehrer PJ; Einhorn LH
J Clin Oncol; 1994 Jun; 12(6):1245-50. PubMed ID: 7515413
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of chemotherapy with carboplatin, epirubicin, and escalating dose of VP-16 with G-CSF support in extensive small cell lung cancer.
Gridelli C; D'Aprile M; Palmeri S; Curcio C; Rossi A; Gebbia V; Veltri E; Pepe R; Pistillucci G; Bianco AR
Am J Clin Oncol; 1996 Dec; 19(6):589-91. PubMed ID: 8931678
[TBL] [Abstract][Full Text] [Related]
16. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.
Aapro MS; Cameron DA; Pettengell R; Bohlius J; Crawford J; Ellis M; Kearney N; Lyman GH; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
Eur J Cancer; 2006 Oct; 42(15):2433-53. PubMed ID: 16750358
[TBL] [Abstract][Full Text] [Related]
17. The limits of chemotherapy dose intensification using granulocyte colony stimulating factor alone in extensive small cell lung cancer.
Trillet-Lenoir V; Soler P; Arpin D; Bohas C; Riou R; Court-Fortune I; Ecochard D; Perol M; Cordier JF
Lung Cancer; 1996 Jun; 14(2-3):331-41. PubMed ID: 8794414
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy and safety of mecapegfilgrastim in small cell lung cancer as primary prophylaxis of neutropenia post chemotherapy: a retrospective analysis.
Gu X; Zhang Y
Ann Palliat Med; 2021 Jul; 10(7):7841-7846. PubMed ID: 34353071
[TBL] [Abstract][Full Text] [Related]
19. EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer.
Repetto L; Biganzoli L; Koehne CH; Luebbe AS; Soubeyran P; Tjan-Heijnen VC; Aapro MS
Eur J Cancer; 2003 Nov; 39(16):2264-72. PubMed ID: 14556916
[TBL] [Abstract][Full Text] [Related]
20. Granulocyte colony-stimulating factors used in clinical practice: PoloNord Registry-Based Cohort Italian Study.
Fagnani D; Isa L; Verga MF; Nova P; Casartelli C; Filipazzi V; Danova M; Farina G; Pugliese P; Fava S; Bertolini A; Cimminiello C; Boracchi P; Marano G; Panzarino C;
Tumori; 2014; 100(5):491-8. PubMed ID: 25343541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
